News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News Cygnet.One strengthens global e-Invoicing capabilities with expanded accreditations and enhanced support for Malaysia’s LHDN & MDEC framework News Smmwiz Highlights Infrastructure Maturity as the SMM Panel Industry Evolves in 2026 News HKTDC’s response to World Trade Organization’s latest report News The Full Spectrum of K-Culture in One Place: “2026 MyK FESTA” to Open June 25 News Iconic Brand Group Launches Tampa-Based Business Consulting Firm and Marketing Agency Built by Proven Operators News RJM Design Group Selected to Lead Design of Ontario Sports Empire, Western United States’ Largest Multi-Sport Complex
